Investor Webinar April 2025
Arovella Therapeutics is pleased to announce it will hold an investor webinar for shareholders and interested parties. The webinar will provide an update following the release of the Company’s Appendix 4C quarterly while outlining next steps for Arovella throughout the rest of 2025 as it moves toward Phase 1 in-human trials.
Presenting on the webinar will be CEO and MD Dr Michael Baker.
Details of the Investor Webinar are below:
Time: 11:00 AM (AEST)
Date: Tuesday 29 April 2025
Further details on how to attend will be provided by email following registration.
A webinar recording will be made available via the Company’s website and social media channels following the event.
Questions can be submitted on the day or sent in advance to investor@arovella.com.
